银屑病关节炎患者接受TNF抑制剂治疗后的实体癌总体及亚型风险:北欧队列研究
该北欧五国队列研究纳入9655例首次使用TNF抑制剂的银屑病关节炎患者,与未使用生物制剂的患者及普通人群比较,发现TNF抑制剂暴露未增加实体癌总体风险(校正HR 1.0, 95%CI 0.9-1.2 vs 临床登记队列;0.8, 0.7-1.0 vs 患者登记队列),也未增加八种常见癌症类型的风险。
要点
- TNF抑制剂治疗银屑病关节炎患者实体癌总体风险与未使用生物制剂者相当。
- 未观察到八种常见癌症类型风险显著增加。
- 与普通人群相比,实体癌总体标准化发病比无显著升高。
核心结论
- 在五个北欧国家的大型队列中,TNF抑制剂治疗的银屑病关节炎患者实体癌总体风险及八种常见癌症类型风险均未增加。
研究设计与样本
- 基于北欧临床风湿病登记(SRQ/ARTIS、DANBIO、NOR-DMARD、ROB-FIN、ICEBIO)识别2001-2017年首次使用TNF抑制剂的银屑病关节炎患者9655例。
- 通过链接国家癌症登记收集实体癌总体及八种癌症类型的发病信息,采用Cox回归估计风险比(HR),并计算标准化发病比(SIR)。
主要发现
- TNF抑制剂暴露组中识别出296例实体癌,随访55 850人年。
- 与临床登记中未使用生物制剂患者相比,实体癌总体校正HR为1.0(95%CI 0.9-1.2)。
- 与国家患者登记中未使用生物制剂患者相比,实体癌总体校正HR为0.8(95%CI 0.7-1.0)。
- 所研究的任何癌症类型均未显示风险显著增加。
- TNF抑制剂治疗患者与普通人群相比,实体癌总体SIR为1.0(95%CI 0.9-1.1)。
临床怎么用
- 对于银屑病关节炎患者,使用TNF抑制剂时无需因实体癌风险增加而过度担忧,但仍应按常规进行癌症筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA). METHODS: From the Nordic clinical rheumatology registers (CRR) here: SRQ/ARTIS (Sweden), DANBIO (Denmark), NOR-DMARD (Norway), ROB-FIN (Finland) and ICEBIO (Iceland) we identified PsA patients who started a first TNFi 2001-2017 (n = 9655). We identified patients with PsA not treated with biologics from (i) the CRR (n = 14 809) and (ii) the national patient registers (PR, n = 31 350). By linkage to the national cancer registers, we collected information on incident solid cancer overall and for eight cancer types. We used Cox regression to estimate hazard ratio (HR) with 95% CI of cancer (per country and pooled) in TNFi-exposed vs biologics-naïve, adjusting for age, sex, calendar period, comorbidities and disease activity. We also assessed standardized incidence ratios (SIR) in TNFi-exposed PsA vs the general population (GP). RESULTS: We identified 296 solid cancers among the TNFi-exposed PsA patients (55 850 person-years); the pooled adjusted HR for solid cancer overall was 1.0 (0.9-1.2) for TNFi-exposed vs biologics-naïve PsA from the CRR, and 0.8 (0.7-1.0) vs biologics-naïve PsA from the PRs. There were no significantly increased risks for any of the cancer types under study. The pooled SIR of solid cancer overall in TNFi treated PsA vs GP was 1.0 (0.9-1.1). CONCLUSION: In this large cohort study from five Nordic countries, we found no increased risk of solid cancer in TNFi-treated PsA patients, neither for solid cancer overall nor for eight common cancer types.
引用
- Hellgren K, Ballegaard C, Delcoigne B, et al. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study. Rheumatology (Oxford). 2021. PMID: 33401297. doi:10.1093/rheumatology/keaa828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。